Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2006-2010 <u>Obs</u> SIR 95% CI <u>Obs</u> 95% CI Exp Exp SIR

	0.00	<u> </u>	<u> </u>	<u>0070 01</u>		000	<u> </u>	<u> </u>	00 70 01
Bladder, Urinary					Melanoma of Skin				
Male	33	27.0	122.1	(84.1-171.5)	Male	20	18.1	110.7	(67.6-171.0)
Female	9	10.8	83.2	(38.0-157.9)	Female	17	15.0	113.4	(66.0-181.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	5.2	152.4	(65.6-300.3)	Male	9	4.7	189.6	(86.5-359.9)
Female	2	4.8	nc	(nc-nc)	Female	6	4.1	146.3	(53.4-318.5)
<u>Breast</u>					Non-Hodgkin Lymphor	<u>na</u>			
Male	0	8.0	nc	(nc-nc)	Male	20	15.7	127.6	(77.9-197.1)
Female	116	109.4	106.0	(87.6-127.1)	Female	15	14.1	106.3	(59.4-175.3)
Cervix Uteri				Oral Cavity & Pharynx					
					Male	8	11.2	71.7	(30.9-141.3)
Female	4	4.0	nc	(nc-nc)	Female	6	5.6	107.5	(39.3-234.0)
Colon / Rectum					<u>Ovary</u>				
Male	26	31.4	82.9	(54.1-121.4)					
Female	30	34.4	87.2	(58.8-124.5)	Female	7	10.0	69.8	(28.0-143.8)
Esophagus					<u>Pancreas</u>				
Male	3	7.3	nc	(nc-nc)	Male	10	8.8	113.5	(54.3-208.8)
Female	3	2.3	nc	(nc-nc)	Female	11	10.6	103.5	(51.6-185.2)
Hodgkin Lymphon	<u>1a</u>				<u>Prostate</u>				
Male	3	2.3	nc	(nc-nc)	Male	100	107.1	93.3	(75.9-113.5)
Female	3	1.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach .				
Male	18	14.8	121.7	(72.1-192.3)	Male	7	6.3	111.3	(44.6-229.4)
Female	8	9.2	86.6	(37.3-170.6)	Female	6	4.1	144.7	(52.8-315.0)
<u>Larynx</u>					<u>Testis</u>				
Male	2	4.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)					
<u>Leukemia</u>					Thyroid				
Male	12	9.9	120.7	(62.3-210.9)	Male	8	6.2	129.4	(55.7-255.0)
Female	8	8.4	95.7	(41.2-188.6)	Female	19	19.4	98.2	(59.1-153.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	10	8.3	120.4	(57.6-221.5)					
Female	0	3.1	nc	(nc-nc)	Female	28	25.2	111.0	(73.7-160.4)
Lung and Bronchus					All Sites / Types				
Male	52	50.7	102.6	(76.6-134.6)	Male	385	371.1	103.8	(93.7-114.7)
Female	49	57.2	85.7	(63.4-113.3)	Female	381	385.6	98.8	(89.1-109.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;